TG Therapeutics Inc

NASDAQ:TGTX   3:59:58 PM EDT
31.55
+0.49 (+1.58%)
Products, Regulatory

TG Therapeutics Completes Rolling Submission Of Biologics License Application To The U.S. Food And Drug Administration

Published: 03/29/2021 12:16 GMT
TG Therapeutics Inc (TGTX) - Tg Therapeutics Completes Rolling Submission of Biologics License Application to the U.S. Food and Drug Administration for Ublituximab in Combination With Ukoniq™(umbralisib) As a Treatment for Patients With Chronic Lymphocytic Leukemia.
Tg Therapeutics Completes Rolling Submission of Biologics License Application to the U.S. Food and Drug Administration for Ublituximab in Combination With Ukoniq™(umbralisib) As a Treatment for Patients With Chronic Lymphocytic Leukemia.